Business
Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF
Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.
About this update from Iqvia Holdings, Inc.
[{"type":"text","content":"Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026","length":168,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, May 27, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.","length":458,"tagName":"p"},{"type":"image","alt":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","displaySize":"","headline":null,"caption":"Rein Logo (PRNewsfoto/Rein Therapeutics, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":226,"url":"https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lUNLcp9yz5L5abyqs4rZrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM5ODtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/21d12d0173749cab9897840a84c884b9","width":400,"height":226}},"href":"https://mma.prnewswire.com/media/2595086/Rein_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We are pleased to have dosed the first patient in our RENEW Phase 2 trial of LTI-03 following initiation of the trial. We are profoundly focused on our mission to rein in fibrosis and look forward to continuing our momentum in the clinic," said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. "We are encouraged by the strong body of evidence supporting LTI-03 as a potentially innovative treatment for patients with IPF whose needs are unmet by the current standard of care (SoC). I am grateful to our team at Rein, the patients, investigators, and staff participating in our trial for the efficient progress that we are making."","length":690,"tagName":"p"},{"type":"text","content":"The RENEW trial is a Phase 2 multi-center, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of LTI-03 in patients with IPF. Rein is collaborating with IQV...